Myocardial infarction (MI) is one of the leading causes of global morbidity and mortality. Although the survival after MI has improved because of ameliorated treatment strategies, including primary percutaneous interventions, the long-term outcome of MI in general remains poor with a 1-year risk for recurrent cardiovascular disease of >10%.
Metabolomics of Left Ventricular Function After STEMI
Percutaneous Intervention in ST Elevation Myocardial Infarction) was designed to study the effects of metformin therapy on LVEF in nondiabetic ST-segment-elevation MI (STEMI) patients undergoing percutaneous coronary intervention. However, in contrast to preclinical findings, metformin did not improve LVEF compared with placebo 4 months post-MI. 5 This result may be explained by interindividual differences in metformin response, raising the possibility that metformin is effective in a subgroup of patients with cardiovascular. Metabolic profiling has emerged as a powerful tool to explore drug effects and factors influencing drug response. [6] [7] [8] Metabolomics is a relatively novel field in omics sciences, which uses high-throughput technologies, such as nuclear magnetic resonance (NMR) spectroscopy, to concurrently quantify a large number of small molecules in different tissues. Although recent studies reported changes in lipid and amino acid concentrations after metformin treatment, [9] [10] [11] no study has yet used large-scale metabolic platforms to investigate the effects of metformin on a wide range of metabolite measures at a time. Furthermore, metabolic profiling has been performed to improve diagnosis and prediction of cardiovascular events. 12, 13 A recent study identified metabolic profiles that discriminate patients with heart failure from healthy controls. 14 Metabolic profiling may thus help identify novel biomarkers of LV function and ISZ to improve risk stratification in patients with MI.
Metabolite concentrations can vary greatly over time and are highly sensitive to environmental influences. Lipid profiles have been shown to change shortly after MI and only gradually return to baseline after several weeks. 15 The predictive value of a biomarker may thus vary over time. We therefore studied metabolic markers of LVEF, ISZ, and metformin response in the GIPS-III cohort at 3 different time points: baseline (on admission), 24 hours post-MI, and 4 months post-MI.
The objective of this ancillary study of the GIPS-III trial was to evaluate the effect of metformin on metabolic profiles in nondiabetic STEMI patients and to identify prognostic markers, which predict LVEF and ISZ 4 months post-MI. Furthermore, we tested whether metformin improved LVEF and ISZ in subgroups of patients, as identified by metabolic profiling.
Methods

Study Population
The GIPS-III study is a randomized trial that included 380 nondiabetic patients undergoing primary percutaneous coronary intervention for STEMI. Participants received a 4-month regimen with either metformin 500 mg 2dd1 or matching placebo 2dd1. The design of the study has been previously described in more detail. 4, 5 All patients provided written informed consent. The study complied with the Declaration of Helsinki and was approved by the Ethics Committee of the University Medical Center Groningen (The Netherlands) and national authorities (NCT01217307). The primary outcome measure was LVEF; the secondary outcome measure was ISZ.
Laboratory Measurements
Nonfasting blood samples were obtained on admission (n=339), 24 hours post-MI (n=329) and 4 months post-MI (n=316). Serum and EDTA-anticoagulated plasma samples were stored at −80°C until analyzed. Metabolic profiling was performed using a high-throughput 1H NMR metabolomics platform. 16 We obtained a total of 233 serum metabolite concentrations and ratios, including 168 lipoprotein subclass measures, 45 lipid-related measures, 5 glycolysis-related metabolites, 9 amino acids, 3 ketone bodies, 2 fluid balance-related metabolites, and 1 inflammatory marker. An overview of all metabolite measures is given in Table I in the Data Supplement.
Cardiac Magnetic Resonance Imaging
LVEF and ISZ were measured by cardiac magnetic resonance imaging (MRI) 4 months after MI as previously described in detail. 4, 5 . Independent cardiologists analyzed all MRI data and assessed LVEF and ISZ, blinded for treatment assignment.
Statistical Analysis
Missing metabolite measures were imputed using random forest imputation as implemented in the R package missForest. 17 Because most metabolite measures showed skewed distributions, they were normalized using rank-based inverse normal transformation within each time point separately. Spearman correlation coefficients were calculated from the metabolite concentrations for each time point (baseline, 24 hours post-MI, and 4 months post-MI) and plotted using the corrplot function of the corrplot package of R. The correlation plots are presented in Figure I in the Data Supplement.
Because many metabolites were highly correlated, principal component analysis was applied to estimate the number of independent tests for multiple testing correction, using the prcomp-function in R. To additionally account for multiple testing at different time points, principal components were calculated across all 3 time points. The first 68 principal components explained >95% of the variation in the metabolite data, yielding an adjusted significance level of P<0.05/68=0.00074.
Unpaired t tests were performed to assess the effect of metformin treatment on metabolite measures. To identify biomarkers predictive of LVEF and ISZ, we analyzed all metabolite measures at each time point separately, using linear regression adjusted for known predictors of ventricular function and medication use: age, sex, baseline N-terminal prohormone of brain natriuretic peptide levels, baseline creatine kinase-MB levels, myocardial blush grade, metformin treatment, and statin treatment (4 months post-MI). To meet the assumption of normality of residuals, we tested different transformations. Because square-root transformation provided the best results, ISZ was square-root transformed. In addition, we performed stratified analyses for LVEF and ISZ. According to current guidelines, 18 LVEF 52% to 72% was categorized as normal ventricular function, LVEF 41% to 51% was defined as mildly abnormal, and LVEF<41% as abnormal for men. Categories were LVEF 54% to 74% for normal ventricular function, LVEF 41% to 53% as mildly abnormal, and LVEF<41% for abnormal for women. ISZ was stratified by tertiles to obtain the same number of strata as with LVEF. Associations of metabolite measures with LVEF categories and ISZ tertiles were assessed using multinomial logistic regression, which provides pairwise comparisons between each level of the outcome variable and a reference level. Finally, we added the interaction term of metformin treatment and metabolite measure to the linear regression models to identify subgroups of patients in whom metformin was effective. R (version 3.02 or higher, http://www.r-project.org/) was used for all statistical analyses.
Results
Patient Characteristics and Metabolite Measures
A total of 380 patients received either metformin placebo treatment. Of these, 109 did not undergo MRI 4 months post-MI or did not provide utilizable scans because of insufficient quality. Details on metformin/placebo treatment, clinical parameters, and conventional lipid and (apo)lipoprotein measures have been published elsewhere. 5, 11 Briefly, metformin treatment resulted in a modest decrease in lowdensity lipoprotein cholesterol (LDL-C) without significant effects on total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, apolipoprotein B, and apolipoprotein A-I when the values after 4 months and after 24 hours were compared (data not shown). 14 Metabolic profiles were quantified in a total of 376 patients. Baseline, 24 hours post-MI, and 4-month post-MI measurements were available from 339, 326, and 316 patients, respectively. Premature dropout was related to neither metformin treatment nor mortality as none of the participants died before MRI. 5 A summary of all metabolite measures can be found in Table  I 
Association of Metabolites With LVEF and ISZ
Results for all metabolite measures tested are shown in Tables II to VII Table  2 ). Notably, all HDL-TG-related measures showed a positive association with LVEF, suggesting a beneficial effect of increased triglyceride content in HDL. We found no association of 24-hour post-MI measurements with mildly abnormal LVEF relative to normal LVEF. In addition, 24 −4 ). Addition of a treatment×metabolite interaction term did not reveal any patient subgroup in whom metformin improved LVEF (Table 3) .
We Table 2 ). Again, our findings suggest a beneficial effect of higher HDL-TG levels. We found no significant treatment×metabolite interactions ( Table 3) .
As shown in Table VIII in the Data Supplement, HDL-TG, M-HDL-TG, S-HDL-TG, and XL-HDL-TG% increased between baseline and 24 hours post-MI and remained relatively stable between 24 hours and 4 months post-MI, except for XL-HDL-TG%, which showed a moderate gain. Similar to HDL-TG, serum triglyceride levels increased between baseline and 24 hours post-MI, but were decreased 4 months after MI.
Effects of Metformin of Metabolic Profiles
Results for all metabolite measures are shown in Table IX in the Data Supplement. To assess baseline differences in metabolic profiles, we compared metabolite measures between the treatment group and controls at baseline. We did not find any difference between the 2 groups at baseline. Table 4 Table 4 . In addition, the phospholipids:total lipids ratio in XL-HDL particles (XL-HDL-PL%) was significantly reduced in the metformin group (median, 29.89% versus 38.79%; P=7.5×10 −5 ).
Discussion
We used 1H NMR spectrometry-based metabolite measures to evaluate the effects of metformin on metabolic profiles of nondiabetic MI patients and to study prognostic metabolites predicting LVEF and ISZ 4 months post-MI. Moreover, we investigated whether metabolic profiling could be used to identify subgroups of patients in whom metformin was effective.
After the 4-month treatment period, we found higher alanine levels and lower XL-HDL-PL% in metformin-treated patients Differences between categories were assessed using multinomial logistic regression adjusted for treatment, age, sex, N-terminal prohormone of brain natriuretic peptide levels, creatine kinase levels, myocardial blush grade, statin use. HDL-TG indicates triglycerides in high-density lipoprotein particles; M-HDL-TG, triglycerides in medium HDL particles; XL-S-HDL-TG, triglycerides in small HDL particles; XS-VLDL-TG%, triglycerides:total lipids ratio in very small very low-density lipoprotein particles; and XS-VLDL-C%, cholesterol:total lipids ratio in very small VLDL particles. *Effects significant after correction for multiple testing (P<7.4×10 − 4).
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when compared with controls. Remarkably, higher triglyceride levels in HDL and several HDL subfractions measured 24 hours post-MI were associated with favorable outcome as inferred from higher LVEF and smaller ISZ 4 months post-MI. Moreover, categorical analysis of LVEF revealed that besides HDL-TG, the composition of XS-VLDL (24 hours post-MI) and L-LDL (baseline) was associated with abnormal LV function 4 months post-MI. We could not identify metabolic profiles associated with treatment benefits from metformin. Similar to our results, the CAMERA (Carotid Atherosclerosis: Metformin for Insulin Resistance) study, a clinical trial investigating the effects of metformin on different amino acids, found substantially increased alanine levels 18 months after treatment onset. 13 Alanine plays a crucial role in the alanine-glucose cycle, in which alanine released by muscle tissue is transported to the liver before it is converted into pyruvate for gluconeogenesis. Findings from animal studies suggest that metformin reduces gluconeogenesis by inhibiting hepatic alanine uptake 19 and by hampering fat-induced changes in the glycolysis metabolic pathway. 20 As a result of reduced uptake into the liver, blood alanine levels may rise in metformin-treated patients. Interestingly, we observed a trend toward increased alanine levels in the metformin group 24 hours post-MI, suggesting rapid effects of metformin on gluconeogenesis.
Numerous randomized controlled trials have studied the effects of metformin treatment on lipid levels in patients with type 2 diabetes mellitus. A recent study in diabetic patients found that metformin lowered total cholesterol and LDL-C. 21 Another study in patients at risk for diabetes mellitus reported changes in lipoprotein subclasses after 1 year of metformin treatment, with reduced particle concentrations of small LDL and elevated large LDL, small HDL, and large HDL. 9 In our recent report, we observed modest decreases in LDL cholesterol, no change in apolipoprotein B, and as a result a small decrease in LDL particle size. 11 In the present study, which used a different NMR-based method, only the phospholipid content of large HDL particles was decreased in response to metformin.
We also tested whether lipoprotein characteristics and metabolite measures at baseline, 24 hours post-MI and 4 months post-MI were associated with 4-month post-MI LVEF and ISZ. We found that increased HDL-TG levels measured 24 hours post-MI were associated with a greater LVEF. In addition, decreased HDL-TG, M-HDL-TG, XL-HDL-TG%, and S-HDL-TG measured 24 hours post-MI predicted higher ISZ. Categorical analysis of LVEF and ISZ provided similar results with more favorable outcomes for patients with higher HDL-TG levels. No metabolite measure showed a significant interaction with metformin treatment, suggesting that there was no metabolic subgroup of patients in whom metformin was effective.
Our findings suggest beneficial effects of higher triglyceride levels in HDL and in HDL subfractions measured 24 ).
hours post-MI. Clinical studies identified low admission triglyceride levels as a risk factor for recurrent cardiovascular events and mortality in patients with STEMI. 22, 23 Likewise, low triglyceride levels are associated with a poor prognosis in patients with stroke. 24 This contrasts with findings from large-scale case-control and prospective cohort studies indicating that hypertriglycemia is a strong predictor of cardiovascular events, even independent of cholesterol levels. 25, 26 These epidemiological findings, however, apply to individuals who were not studied during the course of an acute coronary event. Similar, paradoxical findings have been obtained for plasma cholesterol levels. Although hypercholesterolemia is an established cardiovascular risk factor in the general population, admission LDL-C levels <70 mg/dL are associated with higher mortality and incidence of heart failure in statin-naive patients with STEMI. 27 The pathogenic mechanisms underlying recurrent cardiovascular events shortly after an acute event are still poorly understood. It is possible that in the acute setting HDL-TG plays a distinct role on cardiovascular outcome.
VLDL is the most important triglyceride carrier in plasma. The triglyceride content of VLDL showed a substantial correlation with HDL-TG 24 hours post-MI ( Figure IB in the Data Supplement). However, only the triglyceride content of very small VLDL particles was associated with LVEF categories. In addition, the TG content of large LDL particles at baseline predicted abnormal LVEF 4 months post-MI. Inhibition of fatty acid uptake by relocation of FAT/CD36 may reduce intracellular fatty acid concentrations, 28 resulting in increased extracellular fatty acid levels and diminished lipolysis of lipid-bound triglycerides. This may initially lead to triglyceride enrichment of VLDL and LDL particles, which subsequently transfer excess triglycerides to HDL particles in exchange for cholesteryl esters by the action of cholesteryl ester transfer protein, thereby increasing the triglyceride content in HDL. 29 In line with this, blood samples of MI patients collected immediately after diagnosis show strong triglyceride enrichment of HDL 2 particles. 30 Higher plasma HDL-TG levels could thus be consequent to inhibition of fatty acid uptake and coincide with diminished fatty acid oxidation and prevention of further myocardial damage. 31 Larger triglyceride-rich particles are converted to small VLDL subfractions as a result of lipase-mediated delipidation, 32 suggesting that triglyceride enrichment may be secondary to initial triglyceride uptake of large VLDL. Larger VLDL particles may be delipidated rapidly, which may explain why the association of triglycerides with LVEF was limited to very small VLDL 24 hours post-MI. Similarly, a major proportion of LDL-TG is derived from large VLDL, 32 which may partly result from cholesteryl ester transfer protein-mediated delipidation of large VLDL. Taken together, early metabolic changes after MI could reflect adaptive mechanisms that promote functional recovery.
Although we observed associations of LVEF categories with 24 hours post-MI measurements of XS-VLDL-TG% and XS-VLDL-C%, these metabolite measures did not significantly predict LVEF when LVEF was analyzed as a continuous variable. However, the regression model with continuous outcome assumes linearity between metabolite measures and LVEF, whereas categorical analysis of LVEF in combination with multinomial logistic regression renders the model sensitive to nonlinear associations. As shown in Figure 2A , HDL-TG, M-HDL-TG, and S-HDL-TG follow a linear trend across the three LVEF categories, whereas XS-VLDL-TG% and XS-VLDL-C% display nonlinear trends.
Limitations
The GIPS-III trial was originally designed to assess differences in LVEF between metformin-treated patients and controls. We conducted 68 independent tests, raising the possibility that our study was not powered to detect smaller changes. However, we were able to detect a significant effect for alanine levels, which were only slightly increased in the metformin group (median difference, 0.03 mmol/L), demonstrating sufficient power to perform a metabolic profiling analysis. In addition, all patients received intravenous heparin before percutaneous coronary intervention when baseline blood samples were drawn. Heparin stimulates lipolysis and hence acutely reduces plasma triglyceride levels, 33 which is in line with the marked increase in triglyceride levels between baseline and the other time points (Table VIII in the Data Supplement ). Patients with STEMI routinely receive heparin before percutaneous coronary intervention, rendering the results for baseline measurements relevant to clinical settings. These findings measurements should nevertheless be interpreted with caution. Moreover, we performed metabolic profiling in nonfasting blood samples, warranting further research to substantiate our findings under fasting conditions. However, the NMR platform used in our study mainly quantifies lipid measures, which change only slightly after food consumption and show similar associations with cardiovascular risk in fasting and nonfasting individuals. 34 
Conclusions
Our study suggests that metformin treatment started directly after presentation with STEMI produces changes in alanine and XL-HDL-PL% as assessed after 4 months. Higher ).
triglyceride levels in HDL and in HDL subfractions measured 24 hours post-MI were predictive of better LVEF and smaller ISZ 4 months post-MI. HDL-TG may thus serve as an early biomarker of LV dysfunction in patients with STEMI. However, further studies are required to substantiate the clinical significance of HDL-TG in cardiovascular risk prediction and to investigate the biological mechanism underlying associations of metabolic biomarkers with recurrent cardiovascular events. Our findings emphasize the utility of high-throughput metabolic profiling as a tool to study drug effects and to identify prognostic biomarkers of LVEF and ISZ.
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